Reading the tape
NYSE: DVA
DaVita Inc.
Healthcare · Medical - Care Facilities
Market Cap
$10.16B
52w High
$159.42
52w Low
$101.00
P/E
17.76
Volume
773.97K
Outstanding Shares
65.94M
Valuation Data Insufficient
The DCF model's fair value estimate is more than 3× the current stock price. This typically indicates unreliable model inputs — such as irregular cash flows or balance sheet distortions — rather than a genuine opportunity, so the valuation is not shown.
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 8.84%Revenue (TTM): 6.46%FCF (TTM): -10.63%P/FCF: 59th pct
What changed
The stock rose 8.84% over the last year. Revenue grew 6.46% over the trailing twelve months. Operating margin moved from 16.31% to 14.91%. Free cash flow declined 10.63% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 14.91%. A decisive move in revenue — currently up 6.46% — would be the clearest signal to resolve the ambiguity.
Company profile
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure.
CEOJavier J. Rodriguez
SectorHealthcare
IndustryMedical - Care Facilities
Employees76,000
IPO dateOct 31, 1995
Valuation
Forward P/E—
EV/EBITDA9.11
Enterprise value$24.07B
Stock splits
Sep 9, 2013↑ Forward
Every 1 shares became 2
Jun 16, 2004↑ Forward
Every 2 shares became 3
Oct 21, 1997↑ Forward
Every 3 shares became 5
Profitability & growth
Revenue growth9.87%
Gross margin30.88%▼17.93%vs FY2024
Operating margin14.91%▼9.65%vs FY2024
ROE-114.7%▼114.84%vs FY2024
Analyst consensus
RatingHold
Target price$168.67▲9.47%
8
Buy
14
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est $2.33 · Revenue est $3.36B
View